Evidence map›Paper›PMID 38708711›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

PAD4 Inhibitor-Functionalized Layered Double Hydroxide Nanosheets for Synergistic Sonodynamic Therapy/Immunotherapy Of Tumor Metastasis.

Di Zhu, Yu Lu, Shuqing Yang, Tingting Hu, Chaoliang Tan, Ruizheng Liang, Yuji Wang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Advanced Therapeutic Approach Based on LDHs-Mimetic Oxidoreductase.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Di ZhuDepartment of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing, 100069, P. R. China.
Yu LuDepartment of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing, 100069, P. R. China.
Shuqing YangState Key Laboratory of Chemical Resource Engineering, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, 100029, P. R. China.
Tingting HuDepartment Electrical and Electronic Engineering, The University of Hong Kong, Pokfulam Road, Hong Kong SAR, 999077, P. R. China.
Chaoliang TanDepartment Electrical and Electronic Engineering, The University of Hong Kong, Pokfulam Road, Hong Kong SAR, 999077, P. R. China.ORCID 0000-0003-1695-5285
Ruizheng LiangState Key Laboratory of Chemical Resource Engineering, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, 100029, P. R. China.
Yuji WangDepartment of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing, 100069, P. R. China.

Funding

Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support ZLRK202308Chinese Institutes for Medical ResearchFundamental Research Funds for the Central Universities XK1803-05National Natural Science Foundation of China 22288102National Natural Science Foundation of China 52122002National Natural Science Foundation of China 52322317Organized Scientific Research Program CX23YZ06
6 · The paper itself

Abstract

Sonodynamic therapy (SDT) is demonstrated to trigger the systemic immune response of the organism and facilitate the treatment of metastatic tumors. However, SDT-mediated neutrophil extracellular traps (NETs) formation can promote tumor cell spread, thus weakening the therapeutic effectiveness of metastatic tumors. Herein, the amorphous CoW-layered double hydroxide (a-CoW-LDH) nanosheets are functionalized with a peptidyl arginine deiminase 4 (PAD4) inhibitor, i.e., YW3-56, to construct a multifunctional nanoagent (a-LDH@356) for synergistic SDT/immunotherapy. Specifically, a-CoW-LDH nanosheets can act as a sonosensitizer to generate abundant reactive oxygen species (ROS) under US irradiation. After loading with YW3-56, a-LDH@356 plus US irradiation not only effectively induces ROS generation and immunogenic cell death, but also inhibits the elevation of citrullinated histone H3 (H3cit) and the release of NETs, enabling a synergistic enhancement of anti-tumor metastasis effect. Using 4T1 tumor model, it is demonstrated that combining a-CoW-LDH with YW3-56 stimulates an anti-tumor response by upregulating the proportion of immune-activated cells and inducing polarization of M1 macrophages, and inhibits immune escape by downregulating the expression of PD-1 on immune cells under US irradiation, which not only arrests primary tumor progression with a tumor inhibition rate of 69.5% but also prevents tumor metastasis with the least number of lung metastatic nodules.

Indexed as

HydroxidesImmunotherapyUltrasonic TherapyAnimalsCell Line, TumorDisease Models, AnimalExtracellular TrapsFemaleHumansMiceMice, Inbred BALB CNanostructuresNeoplasm MetastasisProtein-Arginine Deiminase Type 4Reactive Oxygen SpeciesHydroxidesProtein-Arginine Deiminase Type 4Reactive Oxygen Speciesimmunogenic cell deathimmunotherapylayered double hydroxidessonodynamic therapytumor metastasis

Identifiers

PMID38708711
PMCPMC11234469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.